Adoptive Immunotherapy
Adoptive Immunotherapy - Related Videos
08:06
Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
0 Views •
Cited by 21 •
2010
An experimental lung metastasis and CTL immunotherapy mouse model for analysis of tumor cells-T cell interaction in vivo.
06:51
Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
0 Views •
Cited by 3 •
2019
We describe an approach to reliably generate chimeric antigen receptor (CAR) T cells and test their differentiation and function in vitro and in vivo.
12:55
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
0 Views •
Cited by 17 •
2015
The lymphodepletive and immunomodulatory effects of chemotherapy and radiation standard of care can be leveraged to enhance the antitumor efficacy of T cell immunotherapy. We outline a method for generating EGFRvIII-specific chimeric antigen receptor (CAR) T cells and administering them in the context of glioblastoma standard of care.
08:43
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice
0 Views •
Cited by 2 •
2020
This protocol uses G6PI mixed peptides to construct rheumatoid arthritis models that are closer to that of human rheumatoid arthritis in CD4+ T cells and cytokines. High purity invariant natural killer T cells (mainly iNKT2) with specific phenotypes and functions were obtained by in vivo induction and in vitro purification for adoptive immunotherapy.
01:27
Tumor Immunotherapy
0 Views •
2024
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
FAQs
Recognition depends on antigen receptors carried by the transferred cells. These receptors detect specific targets displayed on diseased cells, including cancerous or infected cells. Once the target is recognized, the cells can activate cytotoxic mechanisms that damage or eliminate it. This receptor-based specificity allows treatment design to focus immune activity on cells bearing a selected target.
These approaches represent different ways to provide targeted immune activity. Tumor-infiltrating lymphocytes are collected from within a tumor, whereas engineered T-cell receptor and chimeric antigen receptor therapies use genetic modification to improve how T cells recognize targets. All three rely on transferred lymphocytes, but they differ in the source or design of their antigen-recognition system.
The treatment depends on transferred cells remaining present and functional long enough to act against diseased cells. If their persistence is limited, the immune response may not continue. Target escape presents a different problem: diseased cells may no longer display the specific target recognized by the transferred cells. Toxicity is an additional concern when immune activity causes harmful effects.
Clinicians first collect immune cells, such as T lymphocytes, from the patient or treatment source. The cells are then activated or genetically modified ex vivo, meaning outside the body, to improve target recognition. Afterward, they are expanded to increase their numbers and reinfused into the patient, where they can engage cells displaying the selected target.
Adoptive immunotherapy is relevant when immune cells need stronger or more specifically directed activity against diseased cells. Its established context includes targeting cancer cells and infected cells through selected antigen receptors. In research, the approach also supports development of targeted treatments for diseases in which identifying and eliminating cells with particular displayed targets is important.
Because transferred cells can be selected, activated, or engineered around particular antigen-recognition properties, the approach provides a way to examine how immune specificity directs cellular attack. In immunology and infection research, investigators can use this framework to connect displayed targets with immune-cell recognition and cytotoxic elimination, while also considering whether target escape limits the response.